¿Cuál es el papel actual de la digoxina en la era de los estudios multicéntricos?
Abstract
La digoxina ha sido desde hace más de 200 años unos de los pilares fundamentales en el tratamiento de la insuficiencia cardiaca, existe una amplia y acumulada experiencia con su empleo en la práctica clínica. Desde hace más de 2 décadas, existe una tendencia creciente a minimizar la utilidad e indicaciones de este medicamento, que no representa interés económico especial para ninguna de las firmas o compañías farmacéuticas, que en última instancia financian, respaldan o promueven la realización de los grandes estudios multicéntricos y ensayos clínicos que dictan las pautas de tratamiento en la cardiología y medicina actual. En el presente trabajo se destaca la importancia e indicaciones actuales de este medicamento, que mantiene su utilidad y vigencia en la era de los grandes estudios multicéntricos y ensayos clínicos.
Downloads
Author Biographies
Benerando Sevilla Pérez
Volfredo José Camacho Assef
Eva de la Nuez Ramos
References
McMurray J, Petrie M, Murdoch D. Clinical epidemiology of heart failure: public and private health burden. Eur Heart J. 1998; 19(Suppl P):9-16.
Hunt S, Backer D, Chin M, Cinquegrani M, Feldman A, Francis G, et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult. J Am Coll Cardiol. 2001; 38:2101-13.
Rodríguez-Artalejo F, BanegasBanegas JR, Guallar-Castillón P. Epidemiología de la insuficiencia cardíaca. Rev Esp Cardiol. 2004; 57:163-70.
McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart. 2000; 83:596-602.
Rose E, Gelinjns A, Moskowitz A. Randomized evaluation of mechanical assistance for the treatment of congestive heart failure (REMATCH) study group. Long-term mechanical left ventricular assistance for end-stage heart failure. N Engl J Med. 2001; 345: 1435-43.
McCullough PA, Philbin EF, Spertus JA, Kaatz S, Sandberg KR, Weaver WD. Confirmation of a heart failure epidemic: findings from the Resource Utilization Among Congestive Heart Failure (REACH) study. J Am CollCardiol. 2002; 39:60-9.
MacIntyre K, Capewell S, Stewart S, Chalmers JWT, Boyd J, Finlayson A, et al. Evidence of improving prognosis in heart failure. Trends in case fatality I 66547 patients hospitalized between 1986 and 1995. Circulation. 2002; 102:1126-31.
Rodríguez Artalejo F, Guallar Castillón P, Banegas Banegas JR, del Rey Calero J. Trends in hospitalization and mortality for heart failure in Spain, 1980-1993. Eur Heart J. 1997; 18:1771-9.
Clelaand JGF, Khand A, Clark A. The heart failure epidemic: exactly how big is it? Eur Heart J. 2001; 2: 623-626.
Anguita Sánchez M, Vallés Bel F. ¿Quién debe tratar la insuficiencia cardíaca? Rev Esp Cardiol. 2001; 54:815-8.
Swedberg K, Cleland J, Dargie H, Drexler H, Follath F, Komajda M, et al. Guías de práctica clínica sobre el diagnóstico y tratamiento de la insuficiencia cardíaca crónica. Versión resumida (actualización 2005). Rev Esp Cardiol. 2005; 58(9):1062-92.
Giverts M, Colucci W, Braunwald E. Clinical aspects of heart failure; pulmonary edema, high-output failure, En: Zipes D, Libby P, Bonow R, Braunwald E, editors. Braunwald's heart disease. A textbook of cardiovascular medicine. 7th ed. Philadelphia: Elsevier Saunders; 2005. p. 539-68.
Cleland JG, Swedberg K, Follath F, Komajda M, Cohen-Solal A, Aguilar JC, et al. The Euro Heart Failure survey programme: a survey on the quality of care among patients with heart failure in Europe. Part 1: patient characteristics and diagnosis. Eur Heart J. 2003; 24:442-63.
Hunt SA, Abraham WT, Chin MH, Feldman AM, Francis GS, Ganiats TG, et al. ACC/AHA 2005 Guideline Update for the diagnosis and management of chronic heart failure in the adult¬ summary article. Circulation. 2005; 112:1825-52.
Gibson DG, Francis DP. Clinical assessment of left ventricular diastolic function. Heart. 2003; 89:231-8.
Oh JK, Hatle L, Tajik AJ, Little WC. Diastolic heart failure can be diagnosed by comprehensive two-dimensional and Doppler echocardiography. J Am Coll Cardiol. 2006; 47:500-6.
Senni M, Tribouilly CM, Rodeheffer RJ, Jacobsen SJ, Evans JM, Bailey KR, et al. Congestive heart failure in the community. A study of all incident cases in Olmsted County, Minnesota, in 1991. Circulation. 1998; 98:282-9.
Vasan RS, Larson MG, Benjamin EJ, Evans JC, Reiss CK, Levy D. Congestive heart failure in subjects with normal versus reduced left ventricular ejection fraction. Prevalence and mortality in a population-based cohort. J Am Coll Cardiol. 1999; 33:1948-55.
García Castelao A, Muñiz J, Sesma P, Castro-Beiras A. Utilización de recursos diagnósticos u terapéuticos en pacientes ingresados por insuficiencia cardiaca: influencia del servicio de ingreso (estudio INCARGAL). Rev Esp Cardiol. 2003; 6:49-56.
González Juanatey JR, Mazón P, Varela A. Insuficiencia cardiaca con función sistólica conservada (insuficiencia cardiaca diastólica). En: Anguita M, editor. Manual de insuficiencia cardiaca. Madrid: Sociedad Española de Cardiología; 2003. p. 91-110.
Zile MR, Brutsaert DL. New concepts in diastolic dysfunction and diastolic heart failure. Part II. Causal mechanisms and treatment. Circulation. 2002; 105:1503-8.
Hamlin NP, Willerson JT, Garan H, Powell WP. The neurogenic vasoconstrictor effect of digitalis on coronary vascular resistance. J Clin Invest. 1974; 53:288-96.
Nohria A, Lewis E, Stevenson LW. Medical management of advanced heart failure. JAMA. 2002; 287:628-40.
Uretsky BF, Young JB, Shahidi FE, Yellen LG, Harrison MC, Jolly MK, et al. On behalf of the PROVED Investigators Group. Randomized study assessing the effect of digoxin withdrawal in patients with mild to moderate chronic congestive heart failure: results of the PROVED trial. J Am Coll Cardiol. 1993; 22: 955-962.
Packer M, Gheorghiade M, Young JB, Constantini PJ, Adams KF, Cody RJ, et al; Radiance Study. Withdraval of digoxin from patients with chronic heart failure treated with angiotensin-converting-enzyme inhibitors. N Engl J Med. 1993; 329: 1-7.
The Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997; 336: 525-533.
Downloads
Published
How to Cite
Issue
Section
License
Those authors who have publications with this journal accept the following terms of the License CC Attribution-NonCommercial 4.0 International (CC BY-NC 4.0):
You are free to:
- Share — copy and redistribute the material in any medium or format
- Adapt — remix, transform, and build upon the material
- The licensor cannot revoke these freedoms as long as you follow the license terms.
Under the following terms:
- Attribution — You must give appropriate credit , provide a link to the license, and indicate if changes were made . You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
- NonCommercial — You may not use the material for commercial purposes .
- No additional restrictions — You may not apply legal terms or technological measures that legally restrict others from doing anything the license permits.
Notices:
You do not have to comply with the license for elements of the material in the public domain or where your use is permitted by an applicable exception or limitation .
No warranties are given. The license may not give you all of the permissions necessary for your intended use. For example, other rights such as publicity, privacy, or moral rights may limit how you use the material.
